Evidence map›Paper›PMID 40686265›Full record

Trial reportCancer medicine2025

Factors Associated With Self-Report Symptom Screening Adherence in Pediatric Cancer Patients.

L Lee Dupuis, Emily Vettese, Catherine Aftandilian, Vibhuti Agarwal, Christina Baggott, Scott M Bradfield, Nicole Crellin-Parsons, David R Freyer, Kara M Kelly, Allison A King and 11 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04614662 (Symptom Screening Linked to Care Pathways for Children With Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04614662 nacompletednot on this map

Symptom Screening Linked to Care Pathways for Children With Cancer: a Cluster Randomized Trial

TypeinterventionalSponsorThe Hospital for Sick ChildrenRan2021 to 2023Enrolled445ConditionsPediatric Cancer, Quality of LifeArmsSPARK Symptom Screening Linked to Feedback to Providers
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

L Lee DupuisProgram in Child Health Evaluative Sciences, the Hospital for Sick Children, Toronto, Ontario, Canada.
Emily VetteseProgram in Child Health Evaluative Sciences, the Hospital for Sick Children, Toronto, Ontario, Canada.
Catherine AftandilianDivision of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Palo Alto, California, USA.
Vibhuti AgarwalNemours Children's Hospital, Orlando, Florida, USA.
Christina BaggottDivision of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Palo Alto, California, USA.
Scott M BradfieldNemours Children's Health, Jacksonville, Florida, USA.
Nicole Crellin-ParsonsProgram in Child Health Evaluative Sciences, the Hospital for Sick Children, Toronto, Ontario, Canada.
David R FreyerCancer and Blood Disease Institute, Children's Hospital los Angeles, Los Angeles, California, USA.
Kara M KellyDepartment of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.
Allison A KingDivision of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
Wade KyonoKapi'olani Medical Center for Women & Children, Honolulu, Hawaii, USA.
Ramamoorthy NagasubramanianNemours Children's Hospital, Orlando, Florida, USA.
Etan OrgelCancer and Blood Disease Institute, Children's Hospital los Angeles, Los Angeles, California, USA.
Michael E RothDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Farha SheraniDriscoll Children's Hospital, Cancer and Blood Disorders Center and Texas A&M University, Corpus Christi, Texas, USA.
Lolie YuLouisiana State University Health Sciences Center/Children's Hospital, New Orleans, Louisiana, USA.
Allison C GrimesPediatric Hematology Oncology, University of Texas Health Science Center at san Antonio, San Antonio, Texas, USA.
Melissa P BeaucheminColumbia University School of Nursing/Herbert Irving Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0003-4058-1586
Lisa M KlesgesDivision of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
George A TomlinsonDepartment of Medicine, Toronto General Hospital, Toronto, Ontario, Canada.
Lillian SungProgram in Child Health Evaluative Sciences, the Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0951-3091

Funding

CIHR PJT-169165NCI NIH HHS R01 CA251112NIH HHS R01CA251112
6 · The paper itself

Abstract

introductionObjective was to describe the association between baseline characteristics and the number of Symptom Screening in Pediatrics Tool (SSPedi) assessments completed over an 8-week period.

methodsThis was a sub-analysis of a cluster randomized controlled trial among 10 sites that were randomized to the intervention group. Participants were English- or Spanish-speaking pediatric patients 8-18 years of age newly diagnosed with cancer. Participants were prompted to complete SSPedi three times weekly for 8 weeks. The outcome was the number of SSPedi assessments completed during the 8-week period. Factors associated with the number of assessments were determined using mixed effects Poisson regression.

resultsAt the 10 intervention sites, 216 patients were included in the analysis. Among these participants, 129 (59.7%) were male, 112 (51.9%) were white, and 83 (38.4%) were Hispanic. The number of SSPedi assessments was significantly higher for participants 11-14 years (rate ratio (RR) 1.13, 95% confidence interval (CI) 1.02-1.25) and 15-18 years (RR 1.15, 95% CI 1.04-1.27) compared to 8-10 years. Participants completed more SSPedi assessments if they were Asian compared to white (RR 1.27, 95% CI 1.10-1.46), non-Hispanic compared to Hispanic (RR 1.15, 95% CI 1.04-1.28) and from families with a household income ≥$60,000 (RR 1.12, 95% CI 1.03-1.21). Participants completed fewer SSPedi assessments if they had solid tumors compared to leukemia (RR 0.91, 95% CI 0.84-0.99).

conclusionAdherence to three-times weekly SSPedi varied by age, race, ethnicity, cancer diagnosis, and family income. This information may facilitate interventions to support routine symptom screening in clinical practice.

trial registrationNCT04614662.

Indexed as

Early Detection of CancerNeoplasmsPatient ComplianceSelf ReportSymptom AssessmentAdolescentChildFemaleHumansMaleadherenceoncologypediatricsymptom screening

Identifiers

PMID40686265
PMCPMC12277931

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.